Q32 Bio Future Growth
Future criteria checks 0/6
Q32 Bio's earnings are forecast to decline at 31% per annum while its annual revenue is expected to grow at 89.4% per year. EPS is expected to decline by 7.4% per annum.
Key information
-31.0%
Earnings growth rate
-7.4%
EPS growth rate
Biotechs earnings growth | 24.1% |
Revenue growth rate | 89.4% |
Future return on equity | n/a |
Analyst coverage | Low |
Last updated | 17 Jun 2024 |
Recent future growth updates
No updates
Recent updates
Earnings and Revenue Growth Forecasts
Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
---|---|---|---|---|---|
12/31/2026 | N/A | -103 | -71 | -64 | 4 |
12/31/2025 | N/A | -68 | -61 | -52 | 4 |
12/31/2024 | N/A | -38 | -52 | -78 | 4 |
3/31/2024 | -10 | -46 | -21 | -21 | N/A |
12/31/2023 | -7 | -54 | -19 | -19 | N/A |
9/30/2023 | 12 | -36 | 2 | 2 | N/A |
12/31/2022 | 7 | -43 | -13 | -11 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: QTTB is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: QTTB is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: QTTB is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: QTTB is forecast to have no revenue next year.
High Growth Revenue: QTTB is forecast to have no revenue next year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if QTTB's Return on Equity is forecast to be high in 3 years time